Patents by Inventor Satishchandra P. Patel
Satishchandra P. Patel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120135940Abstract: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.Type: ApplicationFiled: January 12, 2012Publication date: May 31, 2012Applicant: WATSON LABORATORIES, INC.Inventors: Vinayak T. BHALANI, Satishchandra P. PATEL
-
Patent number: 8119157Abstract: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.Type: GrantFiled: April 7, 2006Date of Patent: February 21, 2012Assignee: Watson Laboratories, Inc.Inventors: Vinyak T. Bhalani, Satishchandra P. Patel
-
Patent number: 7988995Abstract: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.Type: GrantFiled: July 30, 2002Date of Patent: August 2, 2011Assignee: Watson Laboratories, Inc.Inventors: Vinayak T. Bhalani, Satishchandra P. Patel
-
Patent number: 7799340Abstract: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.Type: GrantFiled: March 15, 2007Date of Patent: September 21, 2010Assignee: Watson Laboratories, Inc.Inventors: Vinayak T. Bhalani, Satishchandra P. Patel
-
Patent number: 7670618Abstract: Discloses is a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution containing: (a) a pharmaceutically effective amount of a cyclosporin, in particular Cyclosporin A, (b) a carrier medium which is a mixture of mono- and diesters of propylene glycol with fatty acids having from 8 to 10 carbon atoms or with mixtures of such fatty acids, wherein the monoester makes up less than 60 mol % of the mixture, and (c) a non-ionic surfactant having a hydrophilic lipophilic balance (HLB) greater than 10.Type: GrantFiled: August 4, 2003Date of Patent: March 2, 2010Inventor: Satishchandra P. Patel
-
Patent number: 7153834Abstract: Disclosed is a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution containing: (a) a pharmaceutically effective amount of a cyclosporin, in particular Cyclosporin A, (b) a carrier medium which is a dialkyl ester of an aliphatic or aromatic dioic acid, the alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliphatic or aromatic dioic acid having from 6 to 20 carbon atoms, (c) a co-carrier having a hydrophilic lipophilic balance (HLB) of from 3 to 6, and (d) a non-ionic surfactant having a hydrophilic lipophilic balance (HLB) greater than 10. Examples of the carrier medium are dibutyl sebacate and dibutyl phthalate. Examples of the co-carrier are glycerol monooleate, sorbitan monooleate, glycerol monocaprylate, and sorbitan monolaurate.Type: GrantFiled: August 4, 2003Date of Patent: December 26, 2006Inventor: Satishchandra P. Patel
-
Patent number: 7070802Abstract: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.Type: GrantFiled: March 5, 2001Date of Patent: July 4, 2006Assignee: Pliva, Inc.Inventors: Vinayak T. Bhalani, Satishchandra P. Patel
-
Patent number: 6916785Abstract: Disclosed is a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution containing: (a) a pharmaceutically effective amount of a cyclosporin, in particular Cyclosporin A (b) a carrier medium which is a triglycerol monoester of a fatty acid having from 6 to 30 carbon atoms or mixtures thereof, (c) polyethylene glycol, (d) a non-ionic surfactant having a hydrophilic lipophilic balance (HLB) greater than 10, and (e) optionally, a viscosity reducing agent, the composition being substantially free from ethanol. The preferred carrier medium is triglycerol monooleate. Examples of the viscosity reducing agent are glycerol monocaprylate and glycerol monooleate.Type: GrantFiled: August 4, 2003Date of Patent: July 12, 2005Inventor: Satishchandra P. Patel
-
Publication number: 20040101552Abstract: Disclosed is a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution containing:Type: ApplicationFiled: August 4, 2003Publication date: May 27, 2004Inventor: Satishchandra P. Patel
-
Publication number: 20040102366Abstract: Disclosed is a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution containing:Type: ApplicationFiled: August 4, 2003Publication date: May 27, 2004Inventor: Satishchandra P. Patel
-
Publication number: 20040048789Abstract: Discloses is a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution containing:Type: ApplicationFiled: August 4, 2003Publication date: March 11, 2004Inventor: Satishchandra P. Patel
-
Patent number: 5858401Abstract: The invention comprises a stable solution of cyclosporine forming a polar lipid self-emulsifying drug delivery system ("PLSEDDS"). The composition typically consists of cyclosporine dissolved in a polar lipid, such as a medium chain monoglyceride of C.sub.6 -C.sub.12 fatty acids having a monoglyceride content of at least 50% and a surfactant. The composition provided here instantly forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.Type: GrantFiled: January 22, 1997Date of Patent: January 12, 1999Assignee: Sidmak Laboratories, Inc.Inventors: Vinayak T. Bhalani, Satishchandra P. Patel
-
Patent number: 5043168Abstract: A stable, solid choline magnesium salicylte inclusion complex composition which comprises choline salicylate, magnesium salicylate and magnesium aluminum silicate, and granulation method for preparing the solid inclusion complex composition utilizing liquid salicylate is provided. The invention is also directed to methods of administering the compoitions of the invention to treat osteoarthritis, rheumatoid arthritis, and acute painful shoulder.Type: GrantFiled: April 26, 1990Date of Patent: August 27, 1991Assignee: Sidmak Laboratories, Inc.Inventors: Satishchandra P. Patel, Vinayak T. Bhalani